Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02547818 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease
A Phase 3 study, sponsored by AZTherapies.
- Completed
- Registry status
- Phase 3
- Development phase
- 620
- Enrollment target
NCT02547818 is a Phase 3 study that has completed, run by AZTherapies. The registered enrollment target is 620 participants.
The verdict
NCT02547818, a Phase 3 study, has completed, sponsored by AZTherapies.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 620 participants
- Enrollment target
Study Summary
This is a global Phase III, randomized, double-blinded, placebo-controlled study for subjects with evidence of early AD. The protocol is designed to determine whether ALZT-OP1 combination treatment (ALZT-OP1a + ALZT-OP1b) will slow down, arrests, or reverse cognitive and functional decline, in subjects with evidence of early stage Alzheimer's disease (AD).
Interventions
- DRUG ALZT-OP1a
- DRUG ALZT-OP1b
- OTHER Placebo ALZT-OP1a
- OTHER Placebo ALZT-OP1b
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 620 participants |
| Start Date | 2015-09-15 |
| Est. Completion | 2020-11-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02547818
The ClinicalTrials.gov registry entry for NCT02547818 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 620 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AZTherapies, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which ALZT-OP1a is the first listed.
NCT02547818 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02547818 about?
NCT02547818 is a clinical study titled "Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease". This is a global Phase III, randomized, double-blinded, placebo-controlled study for subjects with evidence of early AD. The protocol is designed to determine whether ALZT-OP1 combination treatment (ALZT-OP1a + ALZT-OP1b) will slow down, arrests, or reverse cognitive and functional decline, in subje...
What is the current status of trial NCT02547818?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 620 participants. The study started on 2015-09-15. Estimated completion is 2020-11-18.
What interventions are being tested in trial NCT02547818?
The interventions under investigation include: ALZT-OP1a (DRUG), ALZT-OP1b (DRUG), Placebo ALZT-OP1a (OTHER), Placebo ALZT-OP1b (OTHER).
Who is sponsoring clinical trial NCT02547818?
This trial is sponsored by AZTherapies, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.